The aggregate value of cancer screenings in the United States: full potential value and value considering adherence.

ABSTRACT:

Background

Although cancer mortality has been decreasing since 1991, many cancers are still not detected until later stages with poorer outcomes. Screening for early-stage cancer can save lives because treatments are generally more effective at earlier than later stages of disease. Evidence of the aggregate benefits of guideline-recommended single-site cancer screenings has been limited. This article assesses the benefits in terms of life-years gained and associated value from major cancer screening technologies in the United States.

Methods

A mathematical model was built to estimate the aggregate benefits of screenings for breast, colorectal, cervical, and lung cancer over time since the start of US Preventive Services Task Force (USPSTF) recommendations. For each type, the

SUBMITTER: Philipson TJ 

PROVIDER: S-EPMC10405449 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature